EDITORIAL SECTION

of the pharmaceutical industrys most senior brand commercial and agency leaders today publicly declared the end of the fragmented software stack that has defined pharma marketing for two decades

Neurizon Therapeutics Limited is pleased to announce that the Bellberry Human Research Ethics Committee HREC has approved the Companys Phase formulation study supporting development of the NUZ

Creatv Bio a Division of Creatv MicroTech Inc Creatv a liquid biopsybased cancer diagnostic testing company recently opened its full service CLIAcertified laboratory in Monmouth Junction NJ

Collegium Pharmaceutical Inc today announced that it has completed the acquisition of AZSTARYS serdexmethylphenidate and dexmethylphenidate a central nervous system CNS stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder ADHD in people years of age and...

Eli Lilly and Company and UNICEF USA have announced a new collaboration to improve prevention and care for noncommunicable diseases NCDs among children and adolescents in low and middleincome countries

Nuvation Bio has completed the transfer of manufacturing processes for IBTROZI taletrectinib to Thermo Fisher Scientificin the United States The medicine is used to treat patients with advanced or metastatic ROSpositive nonsmall cell lung cancer NSCLC

Agios Pharmaceuticals Inc a commercialstage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases today announced the submission of its supplemental New Drug Application sNDA to the US Food and Drug Administration FDA for the US accelerated

Boehringer Ingelheim and Immunitas Therapeutics today announced a global licensing agreement for a preclinical antibody program being developed for chronic inflammatory and autoimmune diseases The program is designed to selectively target cells that play a central role in driving chronic inflammatio...

Gyre Therapeutics Inc an innovative commercialstage biopharmaceutical company with operations in the United States and China today announced that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has accepted its New Drug Application NDA for F hydronidone

Chinas National Medical Products Administration NMPA has granted Breakthrough Therapy Designation to NHWD HCI an oral BET inhibitor developed by Zhejiang Wenda Pharmaceutical Technology Co Ltd